Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: Production process, content and identification of active components

Cytotherapy

Volumn 14, Issue 5, 2012, Pages 540-554

  Fekete, Natalie ^a   Gadelorge, Mélanie ^b   Frst, Daniel ^a   Maurer, Caroline ^a   Dausend, Julia ^a   Fleury Cappellesso, Sandrine ^b   Mailnder, Volker ^a   Lotfi, Ramin ^a   Ignatius, Anita ^c   Sensebé, Luc ^b   Bourin, Philippe ^b   Schrezenmeier, Hubert ^a   Rojewski, Markus Thomas ^a  

^a German Red Cross Blood Transfusion Service Baden Württemberg Hessen and University Hospital Ulm   (Germany)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Blood platelets; Chemokines; Cytokines; Mesenchymal progenitor cells; Mesenchymal stromal cells

Indexed keywords

CD40 LIGAND; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; FIBROBLAST GROWTH FACTOR 2; INTERCELLULAR ADHESION MOLECULE 1; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; RANTES; THROMBOCYTE CONCENTRATE; TRANSFORMING GROWTH FACTOR BETA1; VASCULAR CELL ADHESION MOLECULE 1;

APHERESIS; ARTICLE; BLOOD; BONE MARROW CELL; CELL ISOLATION; CELL LYSATE; CELL PROLIFERATION; COLONY FORMING UNIT; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; NORMAL HUMAN; PLATELET LYSATE; PRIORITY JOURNAL; THROMBOCYTE;

EID: 84859745736     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2012.655420     Document Type: Article

References (71)

1. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-7.
2. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defi ning multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.
3. Prockop DJ, Brenner M, Fibbe WE, Horwitz E, Le Blanc K, Phinney DG, et al. Defi ning the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010;12:576-8.
4. EMA. The European Agency for the Evaluation of Medicinal Products. Guideline on the Requirements and Controls Applied to Bovine Serum Used in the Production of Immunological Veterinary Medicinal Products. 2002a;EMEA/CVMP/743/ 00.
5. EMA. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products (Draft). 2002b;CPMP/BWP/1793/02.
6. EMA. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products. 2003;EMEA/ 410/01 revision 2.
7. Ng F, Boucher S, Koh S, Sastry KSR, Chase L, Lakshmipathy U, et al. PDGF, TGF-b1, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profi ling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood. 2008;112:295-307.
8. Mimura S, Kimura N, Hirata M, Tateyama D, Hayashida M, Umezawa A, et al. Growth factor-defi ned culture medium for human mesenchymal stem cells. Int J Dev Biol. 2011; 55:181-7.
9. Tyndall A, Walker U, Cope A, Dazzi F, De Bari C, Fibbe W, et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arth Res Ther. 2007;9:301.
10. Burnouf T, Kuo YP, Huang CT, Tseng YH, Lin CT, Su CY. A virally inactivated platelet-derived growth factor/vascular endothelial growth factor concentrate fractionated from human platelets. Transfusion. 2010;50:1702-11.
11. Hammacher A, Hellman U, Johnsson A, Ostman A, Gunnarsson K, Westermark B, et al. A major part of plateletderived growth factor purifi ed from human platelets is a hetero dimer of one A and one B chain. J Biol Chem. 1988;263:16493-8.
12. Hart CE, Bailey M, Curtis DA, Osborn S, Raines E, Ross R, et al. Purifi cation of PDGF-AB and PDGF-BB from human platelet extracts and identifi cation of all three PDGF dimers in human platelets. Biochemistry. 1990;29:166-72.
13. Sensebe L, Krampera M, Schrezenmeier H, Bourin P, Giordano R. Mesenchymal stem cells for clinical application. Vox Sang. 2010;98:93-107.
14. Bourin P, Gadelorge M, Peyrafi tte JA, Fleury-Cappellesso S, Gomez M, Rage C, et al. Mesenchymal progenitor cells: tissue origin, isolation and culture. Transfus Med Hemother. 2008;35:160-7.
15. Klass BR, Grobbelaar AO, Rolfe KJ. Transforming growth factor beta1 signalling, wound healing and repair: a multifunctional cytokine with clinical implications for wound repair, a delicate balance. Postgrad Med J. 2009;85:9-14.
16. Fonsatti E, Maio M. Highlights on endoglin (CD105): from basic fi ndings towards clinical applications in human cancer. J Transl Med. 2004;2:18.
17. Bundesar ztekammer. Richtlinien zur Gewinnung von Blut und Blutbestandteilen und zur Anwendung von Blutprodukten (H amotherapie). 2010;Gesamtnovelle 2005, 2. Richtlinienanpassung 2010.
18. EDQM. European Pharmacopoeia. 7th ed., Chapter 2.6.14. Stuttgart, Germany: Deutscher Apotheker Verlag; 2008.
19. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-41.
20. L e Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroidresistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371:1579-86.
21. Sensebe L, Bourin P, Tarte K. Good manufacturing practices production of mesenchymal stem/stromal cells. Hum Gene Ther. 2011;22:19-26.
22. Reinhardt J, Sthler A, Blmel J. Safety of bovine sera for production of mesenchymal stem cells for therapeutic use. Hum Gene Ther. 2011;22:776.
23. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther. 2004;9:747-56.
24. Sundin M, Ringden O, Sundberg B, Nava S, Gotherstrom C, Le BK. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica. 2007;92:1208-15.
25. Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99:8932-7.
26. Martin MJ, Muotri A, Gage F, Varki A. Human embryonic stem cells express an immunogenic nonhuman sialic acid. Nat Med. 2005;11:228-32.
27. Asher DM. Bovine sera used in the manufacture of biologicals: current concerns and policies of the US Food and Drug Administration regarding the transmissible spongiform encephalopathies. Dev Biol Stand. 1999;99:41-4.
28. Brown P, Will RG, Bradley R, Asher DM, Detwiler L. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: background, evolution, and current concerns. Emerg Infect Dis. 2001;7:6-16.
29. Chase LG, Lakshmipathy U, Solchaga LA, Rao MS, Vemuri MC. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem Cell Res Ther. 2010;1:8.
30. Capelli C, Gotti E, Morigi M, Rota C, Weng L, Dazzi F, et al. Minimally manipulated whole human umbilical cord is a very rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. Cytotherapy. 2011;13:786-801.
31. Ploederl K, Strasser C, Hennerbichler S, Peterbauer-Scherb A, Gabriel C. Development and validation of a production process of platelet lysate for autologous use. Platelets. 2010; 22:204-9.
32. Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, Strunk D, et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells. 2009;27:2331-41.
33. Chevallier N, Anagnostou F, Zilber S, Bodivit G, Maurin S, Barrault A, et al. Osteoblastic differentiation of human mesenchymal stem cells with platelet lysate. Biomaterials. 2010;31:270-8.
34. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol. 2005;205:228-36.
35. Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer E, et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion. 2007;47:1436-46.
36. Su CY, Kuo YP, Lin YC, Huang CT, Tseng YH, Burnouf T. A virally inactivated functional growth factor preparation from human platelet concentrates. Vox Sang. 2009;97:119-28.
37. von Bonin M, Kiani A, Platzbecker U, Schetelig J, Holig K, Oelschlagel U, et al. Third-party mesenchymal stem cells as part of the management of graft-failure after haploidentical stem cell transplantation. Leuk Res. 2009;33:e215-17.
38. Blande IS, Bassaneze V, Lavini-Ramos C, Fae KC, Kalil J, Miyakawa AA, et al. Adipose tissue mesenchymal stem cell expansion in animal serum-free medium supplemented with autologous human platelet lysate. Transfusion. 2009;49: 2680-5.
39. Salvade A, Della MP, Gaddi D, Gatto F, Villa A, Bigoni M, et al. Characterization of platelet lysate cultured mesenchymal stromal cells and their potential use in tissue-engineered osteogenic devices for the treatment of bone defects. Tissue Eng Part C Methods. 2010;16:201-14.
40. Hourfar MK, Jork C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, et al. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodefi ciency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion. 2008;48:1558-66.
41. Roth WK. Quarantine plasma: quo vadis? Transfus Med Hemother. 2010;37:118-22.
42. Schrezenmeier H, Seifried E. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred? Vox Sang. 2010; 99:1-15.
43. Rojewski MT, Weber BM, Schrezenmeier H. Phenotypic characterization of mesenchymal stem cells from various tissues. Transfus Med Hemother. 2008;35:168-84.
44. Fierro F, Illmer T, Jing D, Schleyer E, Ehninger G, Boxberger S, et al. Inhibition of platelet-derived growth factor receptorbeta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif. 2007;40:355-66.
45. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006;24:99-146.
46. Ding W, Knox TR, Tschumper RC, Wu W, Schwager SM, Boysen JC, et al. Platelet-derived growth factor (PDGF)- PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010;116:2984-93.
47. Jenhani F, Durand V, Ben AN, Thallet S, Ben OT, Bejaoui M, et al. Human cytokine expression profi le in various conditioned media for in vitro expansion bone marrow and umbilical cord blood immunophenotyped mesenchymal stem cells. Transplant Proc. 2011;43:639-43.
48. Tokunaga A, Oya T, Ishii Y, Motomura H, Nakamura C, Ishizawa S, et al. PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. J Bone Miner Res. 2008;23:1519-28.
49. Nedeau AE, Bauer RJ, Gallagher K, Chen H, Liu ZJ, Velazquez OC. A CXCL5- and bFGF-dependent effect of PDGF-Bactivated fi broblasts in promoting traffi cking and differentiation of bone marrow-derived mesenchymal stem cells. Exp Cell Res. 2008;314:2176-86.
50. Ponte AL, Marais E, Gallay N, Langonne A, Delorme B, Herault O, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells. 2007;25: 1737-45.
51. Kroeze KL, Jurgens WJ, Doulabi BZ, van Milligen FJ, Scheper RJ, Gibbs S. Chemokine-mediated migration of skin-derived stem cells: predominant role for CCL5/RANTES. J Invest Dermatol. 2009;129:1569-81.
52. Fu X, Han B, Cai S, Lei Y, Sun T, Sheng Z. Migration of bone marrow-derived mesenchymal stem cells induced by tumor necrosis factor-alpha and its possible role in wound healing. Wound Repair Regen. 2009;17:185-91.
53. Kim YS, Park HJ, Hong MH, Kang PM, Morgan JP, Jeong MH, et al. TNF-alpha enhances engraftment of mesenchymal stem cells into infarcted myocardium. Front Biosci. 2009;14:2845-56.
54. Lawson C, Wolf S. ICAM-1 signaling in endothelial cells. Pharmacol Rep. 2009;61:22-32.
55. van de Stolpe A, van der Saag PT. Intercellular adhesion molecule-1. J Mol Med (Berl). 1996;74:13-33.
56. Cheng P, Gao ZQ, Liu YH, Xue YX. Platelet-derived growth factor BB promotes the migration of bone marrow-derived mesenchymal stem cells towards C6 glioma and up-regulates the expression of intracellular adhesion molecule-1. Neurosci Lett. 2009;451:52-6.
57. Ruster B, Gottig S, Ludwig RJ, Bistrian R, Muller S, Seifried E, et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood. 2006; 108:3938-44.
58. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4:206-16.
59. Ip JE, Wu Y, Huang J, Zhang L, Pratt RE, Dzau VJ. Mesenchymal stem cells use integrin beta1 not CXC chemokine receptor 4 for myocardial migration and engraftment. Mol Biol Cell. 2007;18:2873-82.
60. Goedecke A, Wobus M, Krech M, Munch N, Richter K, Holig K, et al. Differential effect of platelet-rich plasma and fetal calf serum on bone marrow-derived human mesenchymal stromal cells expanded in vitro. J Tissue Eng Regen Med. 2011;5:648-54.
61. Lange C, Cakiroglu F, Spiess AN, Cappallo-Obermann H, Dierlamm J, Zander AR. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol. 2007;213:18-26.
62. Kocaoemer A, Kern S, Kluter H, Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells. 2007; 25:1270-8.
63. Flemming A, Schallmoser K, Strunk D, Stolk M, Volk HD, Seifert M. Immunomodulative effi cacy of bone marrowderived mesenchymal stem cells cultured in human platelet lysate. J Clin Immunol. 2011;31:1143-56.
64. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D. Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther. 2010;1:2.
65. Halfon S, Abramov N, Grinblat B, Ginis I. Markers distinguishing mesenchymal stem cells from fi broblasts are downregulated with passaging. Stem Cells Dev. 2011;20: 53-66.
66. Zhang A, Wang Y, Ye Z, Xie H, Zhou L, Zheng S. Mechanism of TNF-alpha-induced migration and hepatocyte growth factor production in human mesenchymal stem cells. J Cell Biochem. 2010;111:469-75.
67. Egea V, von BL, Schichor C, Berninger B, Popp T, Neth P, et al. TNF-alpha respecifi es human mesenchymal stem cells to a neural fate and promotes migration toward experimental glioma. Cell Death Differ. 2011;18:853-63.
68. Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L, et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res. 2008;18:846-57.
69. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007;149:353-63.
70. Singer NG, Caplan AI. Mesenchymal stem cells: mechanisms of infl ammation. Annu Rev Pathol. 2011;6:457-78.
71. de Vasconcellos JF, Laranjeira ABA, Zanchin NIT, Otubo R, Vaz TH, Cardoso AA, et al. Increased CCL2 and IL-8 in the bone marrow microenvironment in acute lymphoblastic leukemia. Ped Blood Cancer. 2011;56:568-77.